MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
pembrolizumab Sensitive: A1 - Approval
Ann Oncol - 2 weeks (New A1)
|
pembrolizumab Sensitive: A1 - Approval
Ann Oncol - 2 weeks - (New C3)
|
NTRK3 fusion
|
Small Intestinal Carcinoma
|
NTRK3 fusion
|
Small Intestinal Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
gemcitabine + docetaxel Sensitive: A2 - Guideline
|
gemcitabine + docetaxel Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Small Intestinal Carcinoma
|
NTRK1 fusion
|
Small Intestinal Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Small Intestinal Carcinoma
|
NTRK2 fusion
|
Small Intestinal Carcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
LV5FU2 Sensitive: A2 - Guideline
|
LV5FU2 Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
pembrolizumab + ipilimumab Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
FOLFIRI Sensitive: A2 - Guideline
|
FOLFIRI Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
paclitaxel + gemcitabine Sensitive: A2 - Guideline
|
paclitaxel + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Small Intestinal Carcinoma
|
NTRK1 fusion
|
Small Intestinal Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Small Intestinal Carcinoma
|
NTRK2 fusion
|
Small Intestinal Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Small Intestinal Carcinoma
|
NTRK3 fusion
|
Small Intestinal Carcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
GTX Sensitive: A2 - Guideline
|
GTX Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
FOLFOXIRI Sensitive: A2 - Guideline
|
FOLFOXIRI Sensitive: A2 - Guideline
|
No biomarker
|
Small Intestinal Carcinoma
|
No biomarker
|
Small Intestinal Carcinoma
|
mFOLFOX6 Sensitive: A2 - Guideline
|
mFOLFOX6 Sensitive: A2 - Guideline
|
MSI-L/dMMR
|
Small Intestinal Carcinoma
|
MSI-L/dMMR
|
Small Intestinal Carcinoma
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
RET fusion
|
Small Intestinal Carcinoma
|
RET fusion
|
Small Intestinal Carcinoma
|
selpercatinib Sensitive: C1 - Off-label
|
selpercatinib Sensitive: C1 - Off-label
|
PTEN mutation + MSI-H/dMMR
|
Small Intestinal Carcinoma
|
PTEN mutation + MSI-H/dMMR
|
Small Intestinal Carcinoma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
MSI-H/dMMR + TMB-L
|
Small Intestinal Carcinoma
|
MSI-H/dMMR + TMB-L
|
Small Intestinal Carcinoma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
VEGFA overexpression
|
Small Intestinal Carcinoma
|
VEGFA overexpression
|
Small Intestinal Carcinoma
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|
MSI-H/dMMR + TMB-H + PD-L1 overexpression
|
Small Intestinal Carcinoma
|
MSI-H/dMMR + TMB-H + PD-L1 overexpression
|
Small Intestinal Carcinoma
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
nivolumab + ipilimumab Sensitive: C4 – Case Studies
|
BRAF V600E + MSI-H
|
Small Intestinal Carcinoma
|
BRAF V600E + MSI-H
|
Small Intestinal Carcinoma
|
CAPOX + BEV Sensitive: C4 – Case Studies
|
CAPOX + BEV Sensitive: C4 – Case Studies
|